Business
Sweden's SyntheticMR Q4 sales rise 42% yr/yr
Sweden's SyntheticMR Q4 sales rise 42% yr/yr
About this update from Syntheticmr Ab
OverviewSweden-based imaging solutions firm's Q4 net sales rose 42% yr/yrCompany's Q4 operating loss narrowedRegulatory approvals in Europe and India expanded market reachOutlookSyntheticMR aims to reach profitability through sharper commercial execution and cost disciplineCompany focuses on U.S. market growth and efficiency improvementsDemand for MRI follow-ups driven by new Alzheimer’s treatments presents growth prospectsResult DriversAPAC GROWTH - Strong performance in APAC driven by OEM sales in Japan, deepening partnershipsREGULATORY APPROVALS - cMRI-ARIA and cMRI received regulatory approvals in Europe and India, expanding market reachU.S. MARKET CHALLENGES - U.S. market underperformed due to difficulty in securing research grants, shifting focus to clinical salesKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesBeatSEK 18 mlnSEK 13 mln (1 Analyst)Q4 Net Income-SEK 6 mlnQ4 Operating Profit-SEK 5.30 mlnAnalyst CoverageThe current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."Wall Street's median 12-month price target for SyntheticMR AB (publ) is SEK2.23, about 99% above its February 5 closing price of SEK1.12Press Release: For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .